Anthrax Vaccine Market Report 2026

The anthrax vaccine market size has grown steadily in recent years. It will grow from $11.77 billion in 2025 to $12.33 billion in 2026 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to high prevalence of anthrax in livestock, government-led vaccination campaigns, research in immunology, limited vaccine production capacity, increased awareness of occupational exposure.

The anthrax vaccine market size is expected to see steady growth in the next few years. It will grow to $14.49 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to development of recombinant and next-generation vaccines, rising demand for human and animal prophylaxis, advancements in vaccine delivery technologies, expansion of biodefense programs, collaborations between pharma and defense sectors. Major trends in the forecast period include advanced vaccine formulations, expanded immunization programs, cold chain & storage innovations, biodefense & pandemic preparedness, government & military vaccination initiatives.

The increasing prevalence of infectious diseases is expected to drive the growth of the anthrax vaccine market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can be transmitted directly or indirectly from one person to another, often resulting in symptoms that range from mild to severe and, in some cases, fatal, depending on the pathogen and the individual's immune response. The rise in infectious diseases is attributed to shifts in global population demographics, urbanization, environmental and land use changes, and alterations in human behavior. The anthrax vaccine is primarily used to protect against anthrax, and its potential for wider application in preventing other infectious diseases is being investigated through research on its immunogenic properties and adaptability. For example, in February 2023, the Council on Foreign Relations, a US-based nonprofit organization, reported that up to 75% of newly identified or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases originated from zoonotic sources. Globally, zoonoses are responsible for 2.7 million human deaths and 2.5 billion cases of disease in people each year. Consequently, the growing prevalence of infectious diseases is fueling the expansion of the anthrax vaccine market.

Major companies operating in the anthrax vaccine market are concentrating on developing innovative products and obtaining FDA approvals for their vaccines to ensure safety, efficacy, and availability for individuals at risk of anthrax exposure. FDA approval guarantees that the vaccine undergoes rigorous testing in clinical trials and is proven safe for public use. This process helps protect individuals from potential adverse effects. For example, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company, received approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly known as AV7909, from the U.S. Food and Drug Administration (FDA). The approval was based on data from a Phase 2 trial assessing Cyfendus's non-interference with antibacterial medications and Phase 3 clinical research comparing the immunogenicity and safety of the vaccine to BioThrax, the previous anthrax vaccine. Additionally, developing safer and more effective adjuvants is essential to address reactogenicity-related issues and improve the overall effectiveness of anthrax vaccines.

In April 2025, Green Cross Corporation, a South Korea-based biopharmaceutical company that develops anthrax and other vaccines and biologics, collaborated with the Korea Disease Control and Prevention Agency (KDCA) for the development and approval of a recombinant anthrax vaccine. Through this collaboration, GC Biopharma and KDCA aim to combine their expertise in biotechnology and public health, integrating GC Biopharma’s recombinant-protein vaccine technology with KDCA’s regulatory and disease prevention capabilities to deliver a safe and effective anthrax vaccine, ultimately enhancing national biodefense preparedness. The Korea Disease Control and Prevention Agency (KDCA) is a South Korea-based government agency responsible for disease control, prevention, and public health management.

Major companies operating in the anthrax vaccine market are Emergent BioSolutions Inc., Indian Immunologicals Limited, GC Biopharma, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company Inc., Botswana Vaccine Institute, VECOL S.A., Biological E Limited, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., China National Biotec Group, Sinovac Biotech Ltd., Instituto Butantan, Razi Vaccine and Serum Research Institute, Federal State Unitary Enterprise Microgen, KM Biologics Co. Ltd., Haffkine Bio-Pharmaceutical Corporation Ltd.

North America was the largest region in the anthrax vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anthrax vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the anthrax vaccine market by increasing the cost of imported raw materials and laboratory equipment, leading to higher production expenses. Vaccine segments such as cell-free protective antigen (PA) vaccines and live attenuated vaccines are most affected, particularly in regions like North America and Europe where import dependency is higher. While tariffs may slow market expansion in some areas, they also incentivize local manufacturing and investment in domestic vaccine production capabilities, potentially enhancing supply chain resilience and long-term market stability.

The anthrax vaccine market research report is one of a series of new reports that provides anthrax vaccine market statistics, including anthrax vaccine industry global market size, regional shares, competitors with a anthrax vaccine market share, detailed anthrax vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the anthrax vaccine industry. This anthrax vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anthrax vaccine is a medical product developed to induce immunity against anthrax, a serious infectious disease caused by the bacterium Bacillus anthracis. The vaccine contains an inactivated form of the anthrax bacterium or its components, prompting the body's immune system to generate antibodies against anthrax toxins. The anthrax vaccine is usually given through injections, starting with initial doses followed by booster shots to sustain immunity over time.

The main vaccine types of the anthrax vaccine include the cell-free protective antigen (PA) vaccine and the live attenuated vaccine. A cell-free protective antigen (PA) vaccine is produced in a laboratory without using live bacteria by synthesizing the protective antigen (PA) protein of the anthrax bacteria. Its applications cover both animal and human use, and it is distributed through various channels such as hospitals, pharmacies, and others.

The anthrax vaccine market consists of sales of avirulent, nonencapsulated bacillus anthracis microaerophilic cultures, aluminum, benzethonium chloride, and formaldehyde. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.